Advertisement


Keynote Lecture: Silvia C. Formenti, MD, on Converting Tumors Into in Situ Vaccines With Radiation Therapy

2017 San Antonio Breast Cancer Symposium

Advertisement

Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses the high therapeutic potential of combining radiotherapy with immunotherapy and findings that show radiation dose and fractionation seem particularly relevant to the success of abscopal responses. The science has now matured to clinical translation.



Related Videos

Breast Cancer

Melinda Telli, MD, on Triple-Negative Breast Cancer: New Clinical Approaches

Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.

Breast Cancer

Eun-Sil Shelley Hwang, MD, on DCIS: Results of the CALGB 40903 Trial

Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstract GS5-05).

Breast Cancer

Matteo Lambertini, MD, on Preserving Fertility in Patients With Early Breast Cancer: Pooled Analysis

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (Abstract GS4-01).

Breast Cancer

Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).

Breast Cancer

Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial

Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).

Advertisement

Advertisement




Advertisement